[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ultrasound-assessment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ultrasound-assessment":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639257",false,"NCT07574255","3D-US Construct on Volumetric Assessment of Lung Disease & Clinical Application","Three-dimensional Ultrasonic Construct on Volumetric Assessment of Lung Disease and Its Clinical Application","Inclusion Criteria:\n\n* Participants suspect with lung lesions referred for ultrasound workup\n\nExclusion Criteria:\n\n* Participants aged \\\u003C 18 years\n* Participants refusal\n* Participants with implanted metal in scanning area interfering data collection\n* Participants who cannot perform breath holding for at least 1 second","ALL","18 Years",{"count":18,"type":19},300,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this observational study is to establish the three-dimensional construct of lung lesion via ultrasound in patients with peripheral lung lesions or any superficial lesion in thoracic fields. The primary question our study aims to answer is:\n\nWhether the 3D ultrasound morphology can reflect lung disease entities? Whether the 3D volumetric follow-up protocol can be standardised to reflect lung disease status?",[24,25,26,27],"Lung Ultrasound","Lung Cancer (Diagnosis)","Peripheral Lung Lesions","Ultrasound Assessment",[29,30,31],"lung ultrasound","three-dimensional ultrasound","peripheral lung lesions","NOT_YET_RECRUITING","2026-05-03",{"date":35,"type":36},"2026-05-07","ACTUAL",{"date":38,"type":19},"2026-05-30",{"date":40,"type":19},"2031-02-28",{"name":42,"class":43},"National Taiwan University Hospital","OTHER",1,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":44},"100623593","NCT07398651","Apremilast and Adalimumab in Psoriatic Arthritis Patients","Comparative Study Between Apremilast and Adalimumab in Psoriatic Arthritis Patients","Inclusion Criteria:\n\n* This study will include 60 adult Psoriatic arthritis patients \\>18 years old, fulfilling the (CASPAR) classification criteria of Psoriatic arthritis and have an inadequate response to methotrexate therapy for at least 3 months.\n\n  * Psoriatic arthritis patients with peripheral musculoskeletal domains (peripheral arthritis, dactylitis and enthesitis) as well as skin and nail domains\n\nExclusion Criteria:\n\n* Patients who received previous biologic agents or Janus kinase inhibitors.\n* Patients with axial and ocular involvement.\n* Current or recent serious infection including tuberculosis or hepatitis B\u002FC .\n* Current or past history of malignancy (within five year).\n* Pregnant or breastfeeding women or women planning pregnancy during the study period .\n* Severe uncontrolled comorbidities such as heart failure, severe liver disease, or chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²) .","70 Years",{"count":53,"type":19},60,"INTERVENTIONAL",[56],"NA","The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate",[59,27,60],"Psoriatic Arthritis","TNF",[62,63,64],"Psoriatic Arthritis Patients:","Apremilast","Adalimumab","2026-02-09",{"date":67,"type":36},"2026-02-10",{"date":69,"type":19},"2026-12-30",{"date":69,"type":19},{"name":72,"class":43},"Tanta University",""]